NCT07619833尚未招募3 期
A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus
Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 510 人开始时间: 2026年6月1日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 510
- 试验地点
- 1
研究概览
简要总结
This study aims to evaluate the efficacy and safety of initial combination therapy with DWP16001 and DWC202518 compared to DWP16001 monotherapy and DWC202518 monotherapy in patients with Type 2 Diabetes Mellitus
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to cooperate and participate in this clinical study after understanding the study explanation, and capable of voluntarily signing the written informed consent form before any assessments are performed.
- •Male or female adult aged ≥18 and ≤80 years. Note: The minimum legal age of adult dependent on local regulations. The legal age of adult in Korea is 19 years, while in Indonesia, it is 18 years.
- •Have been diagnosed with T2DM based on American Diabetes Association (ADA) guidelines (2025) before screening.
- •Participants must meet one of the following conditions at Visit 1 (Screening):
- •Have an HbA1c ≥7.5% and ≤11% at Visit 1 (Screening) and either have never taken oral anti-diabetic medication since diagnosis or have not taken any oral anti-diabetic medication within 12 weeks prior to screening.
- •Have an HbA1c ≥6.5% and ≤10.5% at Visit 1 (Screening) and are currently taking one type of oral anti-diabetic medication at screening.
- •Note: The HbA1c level at Visit 1 can be measured by the local laboratory.
- •Have an FPG <15 mmol/L (270 mg/dL), as measured by local laboratory at Visit
- •Participants must meet all the following conditions at Visit 2 (Baseline):
- •Have an HbA1c ≥7.5% and ≤11%, as measured by the central laboratory at Visit 1-
- •Have an FPG <15 mmol/L (270 mg/dL), as measured by central laboratory at Visit 1-
- •Have a BMI ≥20 kg/m2 and ≤45 kg/m2 at screening.
- •Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening. WOCBP and their partners must use highly effective, medically accepted contraception to prevent pregnancy and must not have pregnancy or fertility plans throughout the study and for at least 4 weeks after the last dose of study medication
- •Male participants must agree to use highly effective, medically accepted contraception and refrain from donating sperm throughout the study and for at least 4 weeks after the last dose of study medication
排除标准
- •Type 1 diabetes mellitus, congenital diabetes, secondary diabetes, or history of diabetic ketoacidosis, diabetic coma, or precoma
- •Severe diabetes-related complications, including proliferative diabetic retinopathy, advanced nephropathy, or severe diabetic neuropathy
- •Clinically significant renal disease, severe gastrointestinal disease or surgery affecting gastrointestinal absorption, pancreatitis, clinically significant urinary/genital infections, dehydration requiring treatment, or uncontrolled thyroid disease
- •Clinically significant cardiovascular or cerebrovascular disease within 6 months prior to screening, including myocardial infarction, unstable angina, stroke, clinically significant arrhythmia requiring treatment, or New York Heart Association (NYHA) class III-IV heart failure
- •Active or untreated malignancy, or clinically significant malignancy within the previous 5 years (except adequately treated localized skin cancers or in situ carcinomas)
- •Hematologic conditions that may interfere with HbA1c measurement
- •Clinically significant endocrine disorders affecting glucose metabolism
- •Known or suspected hypersensitivity to study treatment or related products
- •Screening laboratory abnormalities including:
- •ㆍ Fasting C-peptide ≤0.60 ng/mL ㆍ Triglycerides >500 mg/dL ㆍ eGFR <60 mL/min/1.73m² ㆍ AST or ALT ≥3× upper limit of normal (ULN), or total bilirubin ≥2× ULN
- •Positive hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection meeting protocol-defined criteria
- •Uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg)
- •Prior use of prohibited antidiabetic therapies, including prior antidiabetic combination therapy, thiazolidinediones within 12 weeks, or GLP-1 receptor agonists or insulin within 6 months before screening
- •Use of weight-loss medications within 3 months prior to screening or between screening and baseline
- •Use of systemic corticosteroids at pharmacologic doses within 1 month prior to screening or between screening and baseline
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal CancerRectal NeoplasmsRectal AdenocarcinomaNCT07543848Chongqing University Cancer Hospital20
招募中
1 期
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract CancerNCT07392541Tongji Hospital29
尚未招募
2 期
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)Locally Advanced Oral and Oropharyngeal Squamous Cell CarcinomaNCT07545083Shanghai Zhongshan Hospital26
招募中
2 期
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP2023-507754-33-00Medical Center - University Of Freiburg40
招募中
不适用
A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckNCT07546383The Second Affiliated Hospital of Hainan Medical University32